Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Emily MenendezAdvanced Urothelial Carcinoma | April 12, 2024
A case study studied the results of 4 patients with locally advanced or oligometastatic UC with complete response on imaging.
Read More
Guy Verhovsky, MDUrothelial Carcinoma | April 11, 2024
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Amanda Myers, MDNon-Muscle Invasive Urothelial Carcinoma | April 9, 2024
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Emily MenendezUrothelial Carcinoma | April 9, 2024
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Katy MarshallMuscle Invasive Urothelial Carcinoma | April 8, 2024
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 8, 2024
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
Zachary BessetteUpper Tract Urothelial Carcinoma | April 8, 2024
Patients who undergo RNU have comparative or better long-term outcomes than patients undergoing NSS for organ-localized UTUC.
Emily MenendezUpper Tract Urothelial Carcinoma | April 8, 2024
The nomogram is used preoperatively to determine the probability of nodal tropism.
Katy MarshallUrothelial Carcinoma | April 8, 2024
Researchers assessed recurrence rates, overall survival, and disease progression.
Katy MarshallUpper Tract Urothelial Carcinoma | April 8, 2024
Previous trials have revealed that neoadjuvant chemotherapy is an effective treatment path for patients with high-grade UTUC.
Shilpa Gupta, MDProstate Cancer | April 5, 2024
Dr. Gupta traces the trajectory of her career and describes her commitment to advancing the field through innovative trials.
Leah LawrenceProstate Cancer Diagnostics | April 8, 2024
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
James “Jed” Ferguson III, MD, PhDUpper Tract Urothelial Carcinoma | March 29, 2024
Dr. Ferguson sheds light on a national analysis evaluating the role of lymph node dissection in patients with high-risk UTUC.
James “Jed” Ferguson III, MD, PhDNon-Muscle Invasive Urothelial Carcinoma | March 29, 2024
Dr. Ferguson highlights the latest TAR-210 and TAR-200 data in select patients with non-muscle invasive bladder cancer.
Katy MarshallMuscle Invasive Urothelial Carcinoma | March 27, 2024
Researchers analyzed the effects of NAC on complete and overall response as well as cancer-specific survival after RT.
Gary Kirsh, MDProstate Cancer | March 22, 2024
Dr. Kirsh discusses his distinguished career and the evolution of urology practice in the United States.
Hooman Djaladat, MDUpper Tract Urothelial Carcinoma | March 28, 2024
Dr. Djaladat discusses how the presence of specific biomarkers, such as CK|V oncosomes and D|CK|V cells, correlate with RFS.
Katy MarshallMuscle Invasive Urothelial Carcinoma | March 15, 2024
Patients received 68Ga-FAP-2286 PET, and investigators recorded the SUVmax of 68Ga-FAP-2286 PET-positive lesions.
Alison Jane Birtle, MD, MBBS, MRCP, FRCRUpper Tract Urothelial Carcinoma | March 15, 2024
Dr. Birtle describes the utility of carboplatin versus cisplatin in this regimen and discusses metastasis-free survival.
Alison Jane Birtle, MD, MBBS, MRCP, FRCRUpper Tract Urothelial Carcinoma | March 21, 2024
Dr. Birtle highlights the trial's findings regarding the long-term overall survival benefit of adjuvant chemotherapy.
Advertisement
Advertisement
Advertisement